



# Adroterapia e BNCT al CNAO: il cuore degli atomi per la cura dei tumori complessi


#### Sandro Rossi

Fondazione CNAO

Bari, Campus Universitario 15 Maggio 2024 **RATIONALE of hadrontherapy** 


# **PRECISION - All hadrons**

# **EFFICACY - Carbon ions only**



Difficult and rare tumours: ~5% of all tumours patients

# HADRONTHERAPY IN THE WORLD




# HADRONTHERAPY IN THE WORLD




13 carbon ions centres (+5 in construction)6 of them multi-particle

50.000 patients treated (+5.000/year)




# Early nineties: first hospital based facilities...










# Now, Companies...

- Hitachi
- Varian Medical Systems
- *IBA*
- Protom
- Mevion
- Pronova
- Toshiba
- Sumitomo
- Mitsubishi
- LinearBeam
- Avo
- Bdot medical
- Optivus




# Now, Companies...















#### Not-for-profit private foundation


Created by the Italian Ministry of Health in 2001

With the purpose to introduce hadrontherapy in clinics, pursue research and formation

## The Board is formed by 14 Institutions:

- 5 hospitals
- 3 universities
- 2 research institutes
- 2 public entities (Ministry of Health and Town of Pavia)
- 2 bank foundations

# **CLINICAL Activities at CNAO**





- 1. Chordoma & chondrosarcoma base/spine
- 2. Meningiomas
- 3. Brain tumors (trunk)
- 4. ACC Salivary Glands
  - Orbit tumors including eye melanoma
- 6. Sinonasal carcinoma
- 7. Soft Tissue & bone Sarcoma (every sites)
- 8. Recurrent tumors (retreatment)
- 9. Patients with immulogical desorders
- 10. Pediatric solid tumors

In Italy (60 million inhabitants) estimated cases 1-10: **Protons:** about 5.000 patients/year **Carbons:** about 1.000 patients/year

## Small volumes: ocular melanoma

# Collaboration with INT - Milan: patient selection and tantalium clips






> 450 patients Protons: 60 GyE (4 fx) Local Control >95% Eye preservation >90% Visual function >45%



# **BIG volumes:** sacral chordoma





## Pediatric patients: elective for protons

Less dose to healthy tissues to reduce long term risks of secondary tumours

Year 2022: 46 pat (24 anaesthesia)


Year 2023: 62 pat (24 anaesthesia)






# Non oncological applications: ventricular arrhythmia







	European Journal of Heart Failure
Pub Med.gov	Search PubMed
	Save

Published on.

> Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2056. Online ahead of print.

#### The First-in-Man Case of Non-invasive Proton Radiotherapy to Treat Refractory Ventricular Tachycardia in Advanced Heart Failure


Veronica Dusi <sup>1</sup> <sup>2</sup>, Viviana Vitolo <sup>3</sup>, Laura Frigerio <sup>1</sup> <sup>4</sup>, Rossana Totaro <sup>1</sup> <sup>4</sup>, Adele Valentini <sup>5</sup>, Amelia Barcellini <sup>3</sup>, Alfredo Mirandola <sup>3</sup>, Giovanni Battista Perego <sup>6</sup>, Michela Coccia <sup>2</sup>, Alessandra Greco <sup>4</sup>, Stefano Ghio <sup>4</sup>, Francesca Valvo <sup>3</sup>, Gaetano Maria De Ferrari <sup>7</sup>, Massimiliano Gnecchi <sup>1</sup> <sup>2</sup>, Luigi Oltrona Visconti <sup>4</sup>, Roberto Rordorf <sup>1</sup> <sup>4</sup>



# The origin of CNAO technology


Prof. Ugo Amaldi

TER




▲ Objective: define the optimal hadrontherapy centre without constraints


#### THE CNAO SYSTEM FOR CLINICS AND RESEARCH IP shared by CNAO, INFN, CERN



# THE HEARTH OF CNAO: THE SYNCHROTRON



## Not only accelerators ...





Positioning precision: 0.3 mm linear absolute error 0.1° max. rotational absolute error IR cameras for on-line monitoring of moving targets (100 Hz)

# **Bioengineering: advanced patient positioning and verification systems**

# (Collaboration with G. Baroni - PoliMi)


Robotic cone-beam CT






(Collaboration with GSI

Arc therapy






# **Operations and performances**

Machine running 24/7 - 3 shifts/day


4 maintenance stops per year of 5 days (Thursday to Monday included)

Patient treatments: 7:30 am - 9:30 pm from Monday to Friday


Night shifts and weekends for research, QA, upgrade and maintenance



Years from 2011 to 2023	Year 2023
➤ 4062 running days	≻ 334 gg
> 2985 treatment days	≻ 241 gg
296dd ordinary maintainance	≻ 21 gg
41 dd system breakdown	≻ 0 gg
> System availability: 90.6%	▶ 91.5%
> System reliability (dd): 98.6%	≻ 100%
System reliability (sessions)	> 98.0 % 204 (104+100) vs 9925



# **IONS**: multi-parametric options for optimal individual treatment



Weber, Scifoni, Durante 2021


# **Tumours in moving targets**








M. Lis, et al. Physica Medica 76 (2020) 307-316




# **Dose verification systems**



**Inside** 

Collaboration with INFN, PoliMi, UniPi, UniTo


PET online + Dose profiler (secondaries)



# **Radiomics and dosiomics**

AIRC IG-2020 n. 24946 PI: Prof. Baroni G.






# **Biology guided (MRI) treatment plans**


(Courtesy Chiara Paganelli - chiara.paganelli@polimi.it)




# Patient-specific Microstructural and radiobiological model for persoNalized external beam radiatION therapy in localized tumourS




## **Carbon ions gantry: a challange**







C-Ions Gantries: radius 6...7 m - weight 350...670 tons Only 3 operational worldwide: 1 Germany and 2 Japan




## **CNAO Expansion Project**: present layout




# **CNAO Expansion Project**: layout end 2024



### Level – 1: treatment area, experimental area and technical facilities



### **NEW** Level – 1: treatment area, experimental area and technical facilities




## **Milestones:**


Protontherapy installation starts middle 2024

- ✓ Building completed fall 2024
- ✓ BNCT installation starts fall 2024
- ✓ New technologies ready by fall 2025

# **NEW** Level – 1: HITACHI protontherapy




# **NEW** Level – 1: TLS - BNCT



# BNCT technology: tandem


The beam starts out as a negative hydrogen ion beam; we then pass it through the accelerator where we scrape the electrons off the hydrogen atom which makes it a proton beam and we accelerate it to the Mega Voltage energy range.






(Courtesy of TAE Life Sciences)

## **Radioprotection** studies and authorization procedures



# The "White Book"



#### FONDAZIONE CNAO

A. Charalampopoulou, G. Di Turi, A. Facoetti, J. Franzetti, M. Ferrarini, L. Licitra, G. Magro, S. Molinelli, M. Necchi, E. Orlandi, A. Serra, S. Rossi, G. Vago

#### ISTITUTO NAZIONALE DI FISICA NUCLEARE (INFN) D. Bettoni, P. Cirrone, V. Conte, O. Nicrosini, I. Postuma, A. Retico, V. Vercesi

#### **POLITECNICO DI MILANO** S. Agosteo, A. Pola, A. Pedotti

#### UNIVERSITÀ DEGLI STUDI DI PAVIA

S. Altieri, F. Ballarini, C. Ferrari, F. Forneris, P. Pedrazzoli, N. Protti, G. Zanoni

#### CERN

M. Silari

#### IRCCS POLICLINICO SAN MATTEO V. Bellotti, F. Bocchio, M. Calvi, B. Croesi, G. Galli, V. Rosti

#### **TAE LIFE SCIENCE** B. Bauer, R. Hill, R. Johnson, C. Lee, P. Stafford, J. Styron, A. Theriault, A. Raitano

#### UNIVERSITÀ DEGLI STUDI DI MILANO

G. Gambarini

#### **UNIVERSITÀ DI PISA** F. d'Errico

# The 'White Book'

### TECHNOLOGY AND INFRASTRUCTURE

M. Ferrarini, C. Lee, M. Necchi, S. Rossi, P. Stafford, A. Theriault

### 2 EXPERIMENTAL AND ENVIRONMENTAL DOSIMETRY

S. Agosteo, S. Altieri, V. Conte, M. Ferrarini, F. d'Errico, G. Gambarini, C. Lee, A. Pola, M. Silari, P. Stafford, J. Styron

### 3 DEVELOPMENT OF NEW BORATE COMPOUNDS

V. Bellotti, A. Charalampopoulou, G. Galli, A. Raitano, P. Stafford, G. Vago, G. Zanoni

- 4 BORON MEASUREMENT AND CLINICAL DOSE VERIFICATION C. Lee, S. Molinelli, N. Protti, A. Raitano, A. Retico, P. Stafford
- 5 COMPUTATIONAL DOSIMETRY AND TREATMENT PLANNING P. Cirrone, C. Lee, G. Magro, I. Postuma
- 6 RADIOBIOLOGY

1

F. Ballarini, A. Facoetti, C. Ferrari

#### 7 CLINICAL TRIAL PROCEDURE FOR BNCT

J. Franzetti, G. Galli, L. Licitra, E. Orlandi, P. Pedrazzoli, P. Stafford, A. Theriault

## 8 MEDICAL DEVICE AND DRUG REGULATORY ASPECTS

F. Bocchio, M. Calvi, B. Croesi, G. Di Turi, R. Johnson, L. Licitra, V. Rosti, A. Serra, P. Stafford



# FORMATION: PhD on risk and complexity in High Tech Medical Innovation



# FORMATION: PhD on risk and complexity in High Tech Medical Innovation

The PhD program cover a minimum of 3 years with a full-time commitment.

The educational path consists in both defining and carrying out a research project through advanced training activities, and individual in-depth analysis.

#### **Requirements:**

-Master degree

from the biomedical field (medical doctors, radiotherapists, medical physicists, biologists, biotechnologists),

from the technological field (physicists, engineers, data scientists), from humanities and social areas (law, economy, philosophy, etc).

The Deadline to apply is: June 2024

The lessons start in November 2024



#### For Information : e-mail : hadronacademy@cnao.it

# **THANK YOU!**



#### www.cnao.it

Address

**Fondazione CNAO** 

Via Erminio Borloni, 1





Centro Nazionale di Adroterapia Oncologica

Email info@cnao.it



27100 Pavia



@Fond\_CNAO

**Fondazione CNAO** 

